Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
$47MCash on Hand
28.3mo Cash Runway
Follow FLNA by emailGet an email when FLNA reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about FLNA, unsubscribe in one click. Privacy
📄 Latest SEC Filings in Plain English
Nov 12, 2026 ·
Leadership Filana appointed Jill M. Quigley as a Class I director effective November 8, 2026, with a term expiring at the 2028 annual meeting. She has no committee appointments yet. Ms. Quigley previously served as CEO of Genuiti Therapeutics and COO of Passage Bio. Form 8-K · SEC filing · Press release
Nov 5, 2026 ·
Earnings Reported Q3 2026 results: cash of $47.0M with no debt, R&D of $3.9M, G&A of $7.4M, and a net loss of $10.7M ($0.22/share). Following the September FDA clinical hold lift, patient screening for the Phase 2a simufilam study in TSC-related epilepsy is expected to start by Q1 2027. Form 8-K · SEC filing · Press release
Nov 5, 2026 ·
Quarterly report for the period ended Sep 30, 2026 Form 10-Q · SEC filing
Oct 20, 2026 ·
Legal Fifth Circuit vacated the Texas District Court's class certification order in the securities class action on October 16, 2026. The case returns to the district court for further class certification proceedings on remand. Form 8-K · SEC filing
Sep 22, 2026 ·
Regulatory FDA lifted the full clinical hold on the IND for simufilam in TSC-related epilepsy, clearing the way for a planned 16-week Phase 2a study of 40 subjects aged 12 to 55 at 13 U.S. sites. Patient screening is expected to begin by the first quarter of 2027. Form 8-K · SEC filing · Press release
Sep 18, 2026 ·
Listing Received Nasdaq notice that its stock closed below the $1.00 minimum bid price for 30 consecutive business days. The stock continues trading on the Nasdaq Capital Market as FLNA, with 180 days, or until March 16, 2027, to regain compliance. Form 8-K · SEC filing
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
💰 Cash Runway & Dilution Risk
FLNA holds $47M in cash and short-term investments (as of Sep 30, 2026) and burns about $5M/quarter from operations,
an estimated runway of 28.3 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure:25 · Moderate
Cash runway 28 months
ATM program on file since Nov 2025 +15
Shelf registration (S-3, Nov 2025) +10
Recent financing filings on SEC EDGAR:
Nov 13, 2025 · Shelf registration with ATM program, up to $50M · S-3
Share count 50,269,619 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
Get the full FLNA picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for FLNA and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.